...read the wave

Nano Biz...in depth... im detail


Advance Nanotech and Toumaz Technology Undertake Joint Venture to Produce the Next Generation of Medical Devices

NEW YORK, Feb. 16, 2005 (PRIMEZONE) -- Advance Nanotech, Inc., (OTCBB:AVNA) has announced a joint venture with Toumaz Technology Ltd. to bridge the gap between nanosystems and the macroscopic world.

Bio-Nano Sensium Technologies, the name of the joint venture, will utilize an intelligent, ultra-low power sensor interface, incorporating wireless communication, to create bio-nano sensors that can be implanted within the body to diagnose and treat a wide variety of medical conditions. The development effort will focus on the information and communication technology systems necessary for these sensors to interact with their surrounding environment.

Development of the sensor will leverage the many years of research in ultra-low power circuits and systems at Imperial College of Science, Technology and Medicine, London now exploited by Toumaz Technology Ltd, in their proprietary Advanced Mixed Signal "AMx" technology and wireless transceiver devices. The Bio-Nano Sensium will be capable of power consumption orders of a magnitude lower than current state-of-the-art microprocessors. This nano-power mode of operation is vital to the longer lifetimes, reliability, and stability required in biosensors, especially those that are implanted within the body. The Bio-Nano Sensium will be based on industry-standard Complementary Metal Oxide Semiconductor (CMOS) technology so that not only will it have superior functional features to other devices but also be capable of low-cost production.

Keith Errey, CEO of Toumaz Technologies stated, "We are very excited about this joint venture. Toumaz has worked over the past 4 years in developing a patented, low-power platform technology and we are very pleased to be working with Advance Nanotech to commercialize its use for the next generation of medical devices in the high-value bio-nano sector."

Commenting on the joint venture, Magnus Gittins, CEO of Advance Nanotech, Inc., said, "The Bio-Nano Sensium will play a pivotal role in enabling truly personalized healthcare, where continuous diagnosis can be matched to a treatment program tailored to meet the needs of the individual -- all within a small, implantable medical device. Previous investments made by Toumaz Technology into the platform technologies, which make the Bio-Nano Sensium possible, take us well into the commercialization process."

About Toumaz Technology Ltd.

Toumaz Technology Limited is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company's proprietary AMx(tm) (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.

About Advance Nanotech Inc

Advance Nanotech, Inc. (``Advance'') commercializes innovative nanotechnology. Operating in three areas, electronics, biopharma and materials, Advance leverages relationships with financial and development resources to enable a product focused fast-track commercialization of nanotechnology. Advance has established relationships with academic institutions throughout the world that are at the forefront of nanotechnology research and development. Advance's objective is to invest in patented innovation to bridge early stage product development with valuable markets.

CONTACT: Advance Nanotech, Inc. -- New York
Liza Mullins, (646) 723 8962

Advance Nanotech, Inc. -- London
Charlotte Ramelli +44 (0) 207 451 2466

Toumaz Technology Ltd
Marie Grice +44 (0) 1235 438950

This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -


who is reading
the wave ?

missed some news ?
click on archive photo


or how about joining us


or contacting us ?


about us


our mission